WUXIDAR4 Trademark

Trademark Overview


On Tuesday, September 15, 2020, a trademark application was filed for WUXIDAR4 with the United States Patent and Trademark Office. The USPTO has given the WUXIDAR4 trademark a serial number of 90182832. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 16, 2023. This trademark is owned by WuXi Biologics Co., Ltd.. The WUXIDAR4 trademark is filed in the Pharmaceutical Products, Treatment & Processing of Materials Services, and Computer & Software Services & Scientific Services categories with the following description:

Biomanufacturing for others, namely, manufacturing of biopharmaceuticals using biological organisms in the manufacturing process; Custom manufacture of biopharmaceuticals by pharmaceutical compounders; Manufacturing services for others in the field of biopharmaceuticals

Pharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Drugs for medical purposes, namely, anticancer drugs; Biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for veterinary purposes for treatment of canine disease; Biological prepa...

Biomedical research services; Development of pharmaceutical preparations and medicines; Drug discovery services; Laboratory research services relating to pharmaceuticals; Pharmaceutical drug development services; Pharmaceutical research services; Product development for others; Product quality testing services; Product safety testing services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products for others; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
wuxidar4

General Information


Serial Number90182832
Word MarkWUXIDAR4
Filing DateTuesday, September 15, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 16, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 20, 2021

Trademark Statements


Goods and ServicesBiomanufacturing for others, namely, manufacturing of biopharmaceuticals using biological organisms in the manufacturing process; Custom manufacture of biopharmaceuticals by pharmaceutical compounders; Manufacturing services for others in the field of biopharmaceuticals
Description of MarkThe mark consists of the stylized wording "WuXiDAR4" with the letters "WuXi" in black, the letter "D" in green the letter "A" in blue with legs extending to form the underline beneath the wording in turquoise, yellow, green, blue and yellow, and the letter "R" in turquoise, with the superscript number "4" in green.
Goods and ServicesPharmaceutical preparations for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Drugs for medical purposes, namely, anticancer drugs; Biological preparations for medical purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for human purposes for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Biochemical medicines for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Antibody drug for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Multispecific antibody format for treatment of cancer, infectious disease, metabolic disease, central nervous system disease; Medicines for veterinary purposes for treatment of canine disease; Biological preparations for veterinary purposes for treatment of canine disease
Pseudo MarkWUXIDAR 4; WUXIDAR FOUR
Indication of Colors claimedThe color(s) black, light green, blue, turquoise, green, and yellow is/are claimed as a feature of the mark.
Goods and ServicesBiomedical research services; Development of pharmaceutical preparations and medicines; Drug discovery services; Laboratory research services relating to pharmaceuticals; Pharmaceutical drug development services; Pharmaceutical research services; Product development for others; Product quality testing services; Product safety testing services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research and development of new products for others; Research and development services in the field of antibodies; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 22, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, October 22, 2020
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, October 22, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameWuXi Biologics Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressWuxi, Jiangsu 214092
CN

Party NameWuXi Biologics Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressWuxi, Jiangsu 214092
CN

Trademark Events


Event DateEvent Description
Tuesday, January 17, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 16, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, June 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, June 10, 2022SOU EXTENSION 2 GRANTED
Friday, June 10, 2022SOU EXTENSION 2 FILED
Friday, June 10, 2022TEAS EXTENSION RECEIVED
Thursday, December 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 14, 2021SOU EXTENSION 1 GRANTED
Tuesday, December 14, 2021SOU EXTENSION 1 FILED
Tuesday, December 14, 2021TEAS EXTENSION RECEIVED
Tuesday, June 15, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 20, 2021PUBLISHED FOR OPPOSITION
Wednesday, March 31, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 12, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 23, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 23, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 5, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 5, 2021NON-FINAL ACTION E-MAILED
Friday, February 5, 2021NON-FINAL ACTION WRITTEN
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Friday, October 23, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Thursday, October 22, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 18, 2020NEW APPLICATION ENTERED IN TRAM